Denali Therapeutics: From Revenue Zero to Blockbuster? April 5 Becomes the Key Date

When considering the biopharmaceutical company Denali Therapeutics, one fact stands out immediately: While the company generated revenue continuously from 2018 to 2023, the revenue column for 2024 was completely empty. A fact that would mean the end of the investment story for many other stocks. In this case, however, it is quite the opposite. Denali has yet to bring its own drug to market; previous revenues all came from partnerships. The strategic shift towards its own product pipeline temporarily halted revenues. However, on January 6, 2026,...